Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working party - PubMed
11 hours ago
- #T-cell lymphoma
- #EBMT
- #Allogeneic stem cell transplantation
- Allogeneic hematopoietic stem cell transplantation (allo-SCT) is an established treatment for peripheral T-cell lymphoma (PTCL), especially for relapsed/refractory cases.
- Study analyzed 1958 patients with PTCL-NOS, AITL, and ALK-negative ALCL who underwent allo-SCT between 2010 and 2022.
- Three-year outcomes post-transplant: GvHD-free, relapse-free survival (GRFS) 35.8%, progression-free survival (PFS) 50.9%, and overall survival (OS) 56.8%.
- Relapse incidence (RI) was 25.1%, and non-relapse mortality was 24.1% at three years.
- AITL patients had better survival outcomes compared to PTCL-NOS or ALK-negative ALCL patients.
- Factors associated with worse outcomes: non-complete response at transplantation, haploidentical donor, and higher age.
- Patients in partial response or stable/progressive disease still achieved long-term survival post-allo-SCT.
- Allo-SCT remains a valid option for relapsed/refractory PTCL where targeted therapies are limited.